Oxentia’s Post

Short interview with Santander X on challenges while running a health-tech business, the future of Feyenally and how we benefitted from participating in Santander X Global Challenge. This time I am speaking Polish 🫢🇵🇱📢 #Feyenally #HealthTech #LoveYourEyes https://lnkd.in/dtqCmB5g

Only one week left to apply to the Santander X Global Challenge | Innovation in Healthcare. We're on the hunt for digital innovations that can transform healthcare services by:    ✅ Improving professional practice efficiency  ✅ Facilitating informed public health decisions  ✅ Promoting patient-centred care    Winners receive €120,000 and #SantanderX100 membership, providing access to resources including advice, training, capital, clients, and talent.    Apply by 11 July if you have a solution that enhances patient care and healthcare system efficiency. This may be a step in the right direction to propel your startup or scaleup to new heights with the support of Santander X and the Oxentia Foundation. 📝 It's quick and easy to apply, so don't delay: https://lnkd.in/eUzWxGkM   #SantanderXGlobalChallenge #SantanderXChallenge #HealthEntrepreneur #healthcare #TechForGood #TechForHealth #DigitalWellness 

Only one week left to apply to the Santander X Global Challenge | Innovation in Healthcare. We're on the hunt for digital innovations that can transform healthcare services by:    ✅ Improving professional practice efficiency  ✅ Facilitating informed public health decisions  ✅ Promoting patient-centred care    Winners receive €120,000 and #SantanderX100 membership, providing access to resources including advice, training, capital, clients, and talent.    Apply by 11 July if you have a solution that enhances patient care and healthcare system efficiency. This may be a step in the right direction to propel your startup or scaleup to new heights with the support of Santander X and the Oxentia Foundation. 📝 It's quick and easy to apply, so don't delay: https://lnkd.in/eUzWxGkM   #SantanderXGlobalChallenge #SantanderXChallenge #HealthEntrepreneur #healthcare #TechForGood #TechForHealth #DigitalWellness 

Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, shares his insights in Private Equity Magazine: “If there is one sector in which market depth is not an issue, it is healthcare.” Driven by megatrends like an aging population and groundbreaking advances in science, healthcare remains one of the most promising industries. Read more in PE Magazine about why healthcare continues to lead the way. Link in comments.

One of the key takeaways from the Disruption and Investment Opportunities in the Healthcare Sector panel at #CapTech2024: A $300 million investment is being dedicated to digitizing healthcare operations. 🌐 Even in today’s tech-driven world, many institutions in the sector still rely on hard copy files. This shift toward digitization is a massive step forward, not only to streamline processes but also to open doors for consulting and innovative solutions in the space. The panel also covered a wide range of industry topics, from emerging trends and regulatory challenges to technological advancements shaping the future of healthcare. A must-watch discussion for anyone invested in the evolution of this sector. #CapTech2024 #HealthcareInnovation #DigitalTransformation #InvestmentOpportunities #HealthTech #FutureOfHealthcare #IndustryInsights #BusinessGrowth Jessica Olivier, Dean Kilby, Roderick H. McGeoch AO, LLB, Hon. John Ajaka, George Margelis, Raman Bhalla, Sarah Morgan

Well said, Tony Crisman... Give the below a quick watch for a good summary of many of the key trends impacting and driving healthcare investing in today's landscape. We are continuing to see an uptick in healthcare deal flow at Stout, including both deals currently in market and near-term launches. Please reach out if you wish to discuss further, or if we can be helpful in any way.

Excited to release our 2024 report! Advancing medical tech, expanding healthcare services, or innovating in biotech? Get the HSBC Innovation Banking Venture Healthcare Report, developed by experts. Click here to read the annual report: https://lnkd.in/g_eqnRC5 #HSBCInnovationBanking

Jonathan Norris Healthcare summaries are so insightful and I look forward to them. Here are some highlights: #Biopharma First-financing surge: First-financing dollars more than doubled compared to 2023, despite fewer deals. Fourteen $100M+ mega rounds accounted for 72% of total first-financing dollars. Venture-created deals dominate: Many first-financings were venture-created, focusing on teams with blank checks following big exits and deals in-licensing China assets. Crossover investors drive mega rounds: Many of the 106 $100M+ mega rounds in 2024 featured crossover investors at cycle-high valuations, positioning for large M&A or IPO activity. M&A and IPO activity: M&A saw a sharp increase, with 11 of 17 deals exceeding $1B in total deal value. Eighteen IPOs were recorded, particularly active in Q1 and Q3, focusing on Phase I and Phase II assets. IPO performance was mixed, with the median post-IPO activity down 33%. #MedDevice First-financing struggles: First-financing investment declined due to investors’ concerns about finding Series B leads and an expanding private M&A exit timeline. Series B and insider activity: Series B financings grew, with many achieving up rounds,2 but inside round extensions in Series A also spiked. #Healthtech Focus on underserved groups: Investment continued in companies targeting specialized care in underserved populations, including women’s health, mental health, and senior care. 

📢 Released just ahead of #BiotechShowcase! I’m excited to share Jonathan Norris’s Annual HSBC Innovation Banking Report, a comprehensive and valuable resource for healthcare innovators and investors. Here are some key takeaways: 🔷 #Biopharma: First-financing dollars doubled with 14 $100M+ mega rounds driving 72% of funds. Oncology, autoimmune, and platform companies led growth, with M&A activity surging—11 of 17 deals exceeding $1B. 🔷 #MedDevice: Neurology and NIM made a comeback, while cardiovascular led private M&A. The top 10% of deals captured 60% of all med device dollars. Ceribell achieved the sector’s sole IPO with strong aftermarket performance. 🔷 #HealthTech: Early-stage investment slowed, but AI applications gained momentum. Investments normalized at pre-banking crisis levels, focusing on underserved groups like women’s and mental health. 🔷 #Dx/Tools: First-financing hit a 4-year low, but corporate investors filled the gap. Tempus debuted as the sole IPO with a $5B valuation. Thank you, Jonathan Norris and the HSBC team, for producing such an informative report once again. It’s an excellent resource as we navigate the opportunities of the year ahead! 👏 📖 Download the full report here: https://lnkd.in/ex9Nactq #HealthcareInnovation #VentureCapital #Biopharma #HealthTech